- Home
- DNP vs CELC Comparison
DNP vs CELC Comparison
Compare DNP & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- CELC
- Stock Information
- Founded
- DNP 1986
- CELC 2011
- Country
- DNP United States
- CELC United States
- Employees
- DNP N/A
- CELC N/A
- Industry
- DNP Investment Managers
- CELC Medical Specialities
- Sector
- DNP Finance
- CELC Health Care
- Exchange
- DNP Nasdaq
- CELC Nasdaq
- Market Cap
- DNP 3.8B
- CELC 3.1B
- IPO Year
- DNP N/A
- CELC 2017
- Fundamental
- Price
- DNP $10.14
- CELC $100.06
- Analyst Decision
- DNP
- CELC Strong Buy
- Analyst Count
- DNP 0
- CELC 7
- Target Price
- DNP N/A
- CELC $95.29
- AVG Volume (30 Days)
- DNP 479.6K
- CELC 916.2K
- Earning Date
- DNP 01-01-0001
- CELC 11-12-2025
- Dividend Yield
- DNP 7.88%
- CELC N/A
- EPS Growth
- DNP N/A
- CELC N/A
- EPS
- DNP 2.30
- CELC N/A
- Revenue
- DNP $154,887,179.00
- CELC N/A
- Revenue This Year
- DNP N/A
- CELC N/A
- Revenue Next Year
- DNP N/A
- CELC N/A
- P/E Ratio
- DNP $4.26
- CELC N/A
- Revenue Growth
- DNP 3.30
- CELC N/A
- 52 Week Low
- DNP $8.69
- CELC $7.58
- 52 Week High
- DNP $10.04
- CELC $98.43
- Technical
- Relative Strength Index (RSI)
- DNP 52.96
- CELC 81.86
- Support Level
- DNP $10.01
- CELC $86.56
- Resistance Level
- DNP $10.22
- CELC $96.10
- Average True Range (ATR)
- DNP 0.10
- CELC 5.08
- MACD
- DNP -0.01
- CELC 1.14
- Stochastic Oscillator
- DNP 67.92
- CELC 97.06
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.